Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.93 |
| ▸ | DAO | P14920 | 1/20 | 0.93 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.93 |
| ▸ | CES2 | O00748 | 3/20 | 0.74 |
| ▸ | CES1 | P23141 | 3/20 | 0.74 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL11626217 | 1.00 | TSHR (0.93) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL1312225 | 1.00 | TSHR (0.93) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL3625423 | 1.00 | TSHR (0.93) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL31056757 | 1.00 | TSHR (0.93) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL6575006 | 0.97 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL946804 | 0.97 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL8640540 | 0.97 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL177937 | 0.97 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL324303 | 0.97 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 | |
| Benzoic Acid SCHEMBL6349698 | 0.97 | TSHR (0.88) | TSHRDAONAPRTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | claimed |
| EP-1704146-B1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS (US) | 2010-04-14 | — | — | EP | claimed |
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015066-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-3768661-B1 | DEUTERATED COMPOUNDS AS ROCK INHIBITORS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| EP-4330267-A1 | STABLE ISOQUINOLINE-CORTICOSTEROID CONJUGATES AND USES THEREOF | Aerie Pharmaceuticals, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-112771025-B | Deuterated compounds as ROCK inhibitors | 重庆复创医药研究有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2022232602-A9 | STABLE ISOQUINOLINE-CORTICOSTEROID CONJUGATES AND USES THEREOF | AERIE PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| CN-109563070-B | Fused thiophene derivatives as NAPI-IIB inhibitors | 伊莱利利公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3768661-A1 | DEUTERATED COMPOUNDS AS ROCK INHIBITORS | Fochon Pharmaceuticals, Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019179525-A1 | DEUTERATED COMPOUNDS AS ROCK INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2019-09-26 | — | — | WO | disclosed |
| CN-101679298-B | Fused bicyclic heteroaryl derivatives | DAIICHI SANKYO CO LTD | 2013-10-23 | — | — | CN | disclosed |
| CN-101679298-A | fused bicyclic heteroaryl derivatives | DAIICHI SANKYO CO LTD | 2010-03-24 | — | — | CN | disclosed |
| CN-1886376-A | Pyridine compounds as dipeptidyl dipeptidase-IV inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0315112-A2 | Novel amide compounds | Toyo Boseki Kabushiki Kaisha (JP) | 1989-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | TSHR 1937/4885DAO 1897/4885NAPRT 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.